{"id":14607,"date":"2021-04-30T08:44:34","date_gmt":"2021-04-30T06:44:34","guid":{"rendered":"https:\/\/convergences.online\/hemato\/?p=14607"},"modified":"2024-12-11T13:13:53","modified_gmt":"2024-12-11T12:13:53","slug":"apr-246-et-azacytidine-dans-les-smd-avec-mutation-de-tp53","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/apr-246-et-azacytidine-dans-les-smd-avec-mutation-de-tp53\/","title":{"rendered":"APR-246 et azacytidine dans les SMD avec mutation de TP53"},"content":{"rendered":"
R\u00e9f. : HematoStat.net ; 2(1) : R11<\/div>\n
<\/div>\n<\/p>\n
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes<\/span><\/strong><\/em><\/div>\n
<\/div>\n
\n
<\/div>\n<\/p>\n
Sallman, D. A. et al. Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. <\/span>J. Clin. Oncol. JCO.20.02341 (2021) doi:10.1200\/JCO.20.02341.<\/i><\/a><\/div>\n<\/div>\n
<\/div>\n
\n

R\u00e9sum\u00e9 :<\/h3>\n

L\u2019APR-246 est une mol\u00e9cule orale qui permet de favoriser l\u2019apoptose des cellules qui pr\u00e9sent une mutation de TP53. Quarante patients atteints de syndrome my\u00e9lodysplasique ont \u00e9t\u00e9 inclus dans cette \u00e9tude de phase II. Ils \u00e9taient trait\u00e9s par APR-246 en association \u00e0 l\u2019azacytidine. La toxicit\u00e9 \u00e9tait principalement d\u2019ordre h\u00e9matologique. Le taux de r\u00e9ponse \u00e9tait de 73 % (n=29) avec 50% de r\u00e9ponses compl\u00e8tes. La survie globale \u00e9tait de 14,7 mois en m\u00e9diane, pour les patients r\u00e9pondeurs.<\/p>\n

Dans nos pratiques :<\/h3>\n

Une mol\u00e9cule prometteuse pour une population de patient au pronostic tr\u00e8s d\u00e9favorable qui connait un d\u00e9veloppement difficile. On apprend en effet que l\u2019\u00e9tude de phase 3 qui avait pour crit\u00e8re principal le taux de r\u00e9mission compl\u00e8te semble n\u00e9gative (33,3 % contre 22,4 %, p=0,13). D\u2019autres agents pourraient \u00e9galement apporter une am\u00e9lioration de la prise en charge des patients avec mutation TP53, on pense notamment au magrolimab (anti-CD47).<\/p>\n<\/div>\n

Le regard du statisticien<\/strong><\/h3>\n

Rien \u00e0 redire sur la m\u00e9thodologie employ\u00e9e dans cet essai combinant phases 1b et II. La force de cette publication vient de ses illustrations graphiques, pr\u00e9sentant – outre des courbes de survie classiques – une heatmap <\/em>bien lisible des caract\u00e9ristiques baseline <\/em>et g\u00e9n\u00e9tiques de chaque patient (comme une analyse descriptive mais visuelle), ainsi qu\u2019un graphique d\u00e9crivant la dur\u00e9e des diff\u00e9rentes r\u00e9ponses avec le devenir final de chaque patient \u00e9valuable.<\/p>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":16,"featured_media":14610,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[36],"tags":[66,67,37],"ppma_author":[456],"class_list":["post-14607","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-revue-de-presse","tag-apr-246","tag-azacitidine","tag-smd","author-alexis-genthon"],"aioseo_notices":[],"authors":[{"term_id":456,"user_id":16,"is_guest":0,"slug":"alexis-genthon","display_name":"Alexis GENTHON","avatar_url":{"url":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2023\/06\/Capture-decran-2021-05-07-a-14.25.02.png","url2x":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2023\/06\/Capture-decran-2021-05-07-a-14.25.02.png"},"first_name":"","last_name":"","user_url":"","description":"H\u00e9matologue.\r\nCorrespondance : H\u00f4pital Saint-Antoine \r\nService h\u00e9matologie clinique\r\n184 rue du Faubourg Saint-Antoine 75012 Paris."}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/14607","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=14607"}],"version-history":[{"count":1,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/14607\/revisions"}],"predecessor-version":[{"id":18178,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/14607\/revisions\/18178"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=14607"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=14607"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=14607"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=14607"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}